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Abstract
Purpose: To determine the ability of image-guided high-dose-rate brachytherapy (IG-HDR) to provide local control 
(LC) of lesions in non-traditional locations for patients with heavily pre-treated malignancies.
Material and methods: This retrospective series included 18 patients treated between 2012 and 2014 with IG-HDR, 
either in combination with external beam radiotherapy (EBRT; n = 9) or as monotherapy (n = 9). Lesions were locat-
ed in the pelvis (n = 5), extremity (n = 2), abdomen/retroperitoneum (n = 9), and head/neck (n = 2). All cases were 
performed in conjunction between interventional radiology and radiation oncology. Toxicity was graded based on 
CTCAE v4.0 and local failure was determined by RECIST criteria. Kaplan-Meier analysis was performed for LC and 
overall survival.
Results: The median follow-up was 11.9 months. Two patients had localized disease at presentation; the remain-
der had recurrent and/or metastatic disease. Seven patients had prior EBRT, with a median equivalent dose in 2 Gy 
fractions (EQD2) of 47.0 Gy. The median total EQD2s were 34 Gy and 60.9 Gy for patients treated with monotherapy or 
combination therapy, respectively. Image-guided high-dose rate brachytherapy was delivered in one to six fractions. 
Six patients had local failures at a median interval of 5.27 months with a one-year LC rate of 59.3% and a one-year over-
all survival of 40.7%. Six patients died from their disease at a median interval of 6.85 months from the end of treatment. 
There were no grade ≥ 3 acute toxicities but two patients had serious long term toxicities. 
Conclusions: We demonstrate a good one year LC rate of nearly 60%, and a favorable toxicity profile when utiliz-
ing IG-HDR to deliver high doses of radiation with high precision into targets not readily accessible by other forms 
of local therapy. These preliminary results suggest that further studies utilizing this approach may be considered for 
patients with difficult to access lesions that require LC.
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Purpose
The multidisciplinary oncology team possesses a wide 
armamentarium of tools for achieving local tumor control, 
including thermal and other direct ablation techniques 
performed by interventional radiologists and external 
beam radiation therapy (EBRT) – based techniques deliv-
ered by the radiation oncologist [1, 2]. While these both 
offer excellent local control (LC) with acceptable toxicity 
for appropriately selected patients, there remain scena- 
rios in which achieving LC is challenging. For IR-based 
ablative techniques these include lesions in close proxi-
mity to the vasculature and/or organs-at-risk (OARs) [3] 
and larger lesions [4, 5]. For EBRT-based ablative tech-
niques, the main limitations are lesion size and proximity 
to critical OARs [6, 7, 8].
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Image-guided interstitial high-dose-rate (IG-HDR) 
brachytherapy can overcome some of the limitations of 
both IR-based and EBRT-based ablative techniques [9]. 
With IG-HDR, a collaborative effort between interven-
tional radiologists and radiation oncologists allows de-
livery of high doses of radiation via catheters placed di-
rectly into the target lesion. The sharp dose gradients and 
intra-tumoral heterogeneity provided by HDR allows for 
simultaneous dose-escalation and OAR sparing. There are 
multiple clinical reports using IG-HDR to treat hepatic le-
sions [10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20], recurrent ano-
rectal cancer [21, 22, 23, 24], lung [25], head/neck cancer 
[26, 27, 28, 29], and metastatic melanoma deposits in var-
ious locations [30]. Aside from the latter report, however, 
other reports on the use of IG-HDR to target a variety of 
locations in order to provide local control in patients with 
locally advanced or incurable disease are sparse. We de-
scribe the clinical outcomes of a series of 18 patients treat-
ed with IG-HDR in a wide variety of disease sites, either 
in combination with a course of EBRT or as monotherapy.
Material and methods
Brachytherapy planning and delivery
An institutional review board waiver was approved 
prior to conducting the present retrospective study. 
Eighteen patients treated at the Department of Radiation 
Oncology at the University of California Los Angeles be-
tween 2012 and 2014 were identified. All patients were 
deemed to be inappropriate candidates for a purely inter-
ventional radiology-based ablative approach or EBRT ap-
proach for the lesion in question. These other approaches 
were generally deemed inappropriate due to large size of 
disease and/or proximity to normal organs at risk with 
the small bowel being the most common limiting organ 
at risk. Briefly, a team of radiation oncologists and inter-
ventional radiologists performed the IG-HDR procedures. 
Patients were placed under sedation, and both physicians 
selected the number and trajectory of 15G flexi-guide 
catheters to be placed into the target under image-guid-
ance (ultrasound, CT, or both). A pre-implantation plan 
was used for non-abdominal lesions; due to small bow-
el variation, pre-implantation plans were not used for 
abdominal lesions. Planning target volumes and OARs 
were contoured by the radiation oncologist using imag-
es obtained from a post-implantation CT simulation scan. 
Treatment planning was performed using the inverse 
planning simulation annealing algorithm from Oncentra 
Brachy Treatment Planning System Version 4.3 (Nucle-
tron, an Elekta company, Elekta AB, Stockholm, Sweden). 
Manual graphical optimization was performed prior to 
final plan approval. Prescription doses were chosen con-
servatively on the basis of clinical judgment. Planning was 
performed with the goal of delivering a dose covering the 
target being greater than 90% of the prescription dose. De-
pending on the number of fractions prescribed, the patient 
either completed treatment later that day or was admitted 
to the hospital overnight for further fractions the follow-
ing day. Patients receiving more than one fraction had at 
least six hours in between treatments. A repeat CT simu-
lation scan was performed prior to each fraction and ap-
propriate catheter adjustments were made as necessary. 
For the purposes of comparison, an equivalent dose in 
2 Gy fractions (EQD2) was calculated for each patient, uti-
lizing the formula EQD2 = (dose/fraction*number of frac-
tions)*((dose/fraction + α/β)/(2 + α/β)), where α/β refers 
to tumor radiosensitivity and is set to 10 [31].
Toxicity and follow-up analysis
All patients had follow-up imaging with CT or MRI at 
least three months after treatment, were assessed by a cli-
nician within 12-16 weeks and generally at three month 
intervals thereafter. Acute toxicity was graded utilizing 
the Common Terminology Criteria for Adverse Events 
(CTCAE) version 4 [32], and was derived from a retro-
spective review of follow-up notes. Chronic toxicities 
(defined as occurring > 90 days after IG-HDR) were also 
graded in this fashion. All follow-up dates were measured 
from the date of IG-HDR. Local control was determined 
on the basis of RECIST criteria [33] with progressive dis-
ease categorized as local failure and all other responses 
(stable disease and either partial or complete response) 
treated as LC. A Kaplan-Meier analysis was conducted to 
model LC and overall survival probability.
Results
Patient and treatment characteristics
The median clinical follow-up was 11.9 months 
(range: 4.0-28.5); the median imaging follow-up was 9.15 
months (range: 3.5-28.5). Patient baseline characteristics 
Table 1. Baseline patient characteristics
Age (median, range) 62 (17-87)
Gender
Male (n) 9
Female (n) 10
Lesion size (mean, range) (cm)
Pelvis (n = 5) 5.4 (1.5-13.3)
Extremity (n = 2) 6.5 (2.5-10.5)
Abdomen/Retroperitoneum (n = 9) 6.1 (1.5-12)
Head/Neck (n = 2) 4.8 (3.4-6.2)
Prior EBRT (n) 7
Time from prior EBRT (months) 17.2 (7.7-82.7)
Prior EBRT EQD2 (Gy) 47.0 (44.3-56)
Combination EBRT course* (n) 8
Combination EBRT EQD2 (Gy)  
(median, range)
44.3 (44.3-44.3)
Combination EBRT with chemotherapy (n) 3
Prior receipt of chemotherapy (n) 14
Adjuvant chemotherapy (n) 12
*Patients who received combination external beam radiotherapy (EBRT) cours-
es are those for whom image-guided brachytherapy was performed as a boost 
following EBRT.
EBRT – external beam radiation therapy; EQD2 – equivalent dose in 2 Gy;  
n – number
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are shown in Table 1. Detailed information on the dose/
fractionation regimens for each patient are shown in Ta-
ble 2 and clinical vignettes are provided in Table 3. Two 
patients presented for IG-HDR with primary locally ad-
vanced disease; the remaining 16 patients had locally re-
current and/or metastatic disease at presentation. Seven 
patients had prior EBRT that included the target lesion 
with a median EQD2 of 47.0 Gy and a median treatment 
interval of 17.2 months. Nine patients received IG-HDR 
in combination with a course of EBRT (median EQD2 of 
49.6 Gy for concurrent EBRT doses).
Sample plans are shown in Figure 1, and average 
target dosimetry is shown in Table 4. The average num-
ber of catheters used per case ranged from 7 to 15, de-
pending on site (averages of 15 for pelvis, 13 for extrem-
ity, 7 for abdomen/retroperitoneum, and 12 for head/
neck). In general, the number of catheters used per case 
decreased over time as experience was accumulated. 
Dose fractionation schema varied but the overall aver-
age EQD2 delivered by IG-HDR was 34 Gy for patients 
treated with IG-HDR alone, and 16.7 Gy for patients 
who also received EBRT. The median total EQD2 for 
patients treated with combination IG-HDR and EBRT 
was 60.9 Gy. For the overall population, median EQD2 
was 54.2 Gy.
Clinical outcomes
Six patients had local failures. The median time to local 
failure was 4.07 months (range: 1.0-23.2); among patients 
without local failure, the median imaging follow-up was 
6.92 months (range: 3.47-28.47). Five patients had distant 
progression or developed new metastases after IG-HDR, 
at a median interval of 2.17 months (range: 1.03-11.67). 
Six patients died from their disease, with a median inter-
val of 6.85 months (range: 4.50-23.17). Two of these pa-
tients had no metastases at the time of death, while three 
had metastatic disease at presentation and one developed 
metastatic disease after IG-HDR, Kaplan-Meier curves of 
LC and overall survival are shown in Figure 2, demon-
strating a one-year LC rate of 59.3% and a one-year over-
all survival of 40.7%.
Two of the nine patients with abdominal/retroperi-
toneal lesions had local failures (22.2%), compared with 
neither of the two patients with extremity lesions (0%), 
one of two patients with head/neck lesions (50%), and 
three of five patients with pelvic lesions (60%). Four of 
seven patients who received a total EDQ2 < 45 Gy had 
local failures (57.1%), compared with two out of eleven 
treated with an EQD2 > 45 Gy (18.1%). Five out of nine 
patients treated with IG-HDR alone had local failures 
Table 2. Dose/fractionation data
Patient Lesion location IG-HDR dose/ 
fractionation
Combination EBRT 
dose/fractionation
IG-HDR + combina-
tion EQD2 (Gy)*
Total cumulative 
EQD2 (Gy)**
1 Pelvis 7 Gy × 3 29.8 82.9
2 Pelvis 5 Gy × 2 1.8 Gy × 25 56.8 56.8
3 Pelvis 3 Gy × 3 1.8 Gy × 25 54 54
4 Pelvis 8.5 Gy × 1, 12.5 Gy × 1 59.3 86.1
5 Pelvis 5.5 Gy × 5 35.5 79.8
6 Extremity 3.75 Gy × 4 1.8 Gy × 25 84.3 140.4
7 Extremity 6 Gy × 5 17.2 17.2
8 Abdomen/Retroperitoneum 10 Gy × 1 1.8 Gy × 25 60.9 60.9
9 Abdomen/Retroperitoneum 10 Gy × 1 1.8 Gy × 25 60.9 60.9
10 Abdomen/Retroperitoneum 6 Gy × 1 8 8
11 Abdomen/Retroperitoneum 5.5 Gy × 2 1.8 Gy × 25 58.5 58.5
12 Abdomen/Retroperitoneum 18 Gy × 1 1.8 Gy × 25 86.3 86.3
13 Abdomen/Retroperitoneum 13 Gy × 2 49.8 49.8
14 Abdomen/Retroperitoneum 16 Gy × 1 34.7 34.7
15 Abdomen/Retroperitoneum 10 Gy × 2 33.3 77.6
16 Abdomen/Retroperitoneum 7 Gy × 1 1.8 Gy × 25 54.2 54.2
17 Head/Neck 6 Gy × 6 48 118.8
18 Head/Neck 10 Gy ×1 6 Gy × 5 56.7 56.7
IG-HDR – image-guided high-dose-rate brachytherapy, EBRT – external beam radiotherapy
*EQD2 – equivalent dose in 2 Gy fractions; this was calculated for each patient, utilizing the formula EQD2 = (dose/fraction*number of fractions)*((dose/fraction 
+ α/β)/(2 + α/β)), where α/β refers to tumor radiosensitivity and is set to 10.
**Total cumulative EQD2 incorporates dose from prior treatment.
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Table 3. Case vignettes
Patient Clinical summary
1 61M who presented with recurrent rectal adenocarcinoma, manifesting as an unresectable 6.5 × 7.1 × 13.3 cm pelvic le-
sion eroding through skin. He initially presented with T4bN1M0 rectal adenocarcinoma s/p neoadjuvant chemoradiation, 
an abdominoperineal resection, and adjuvant capecitabine for six cycles. Brachyablation was performed 11.4 months after 
prior EBRT. 
2 61F who presented with newly diagnosed T4aN1M1 squamous cell carcinoma of the vagina. She had a 3.59 cm right pelvic 
sidewall soft tissue implant at presentation. She underwent concurrent chemoradiation followed by an interstitial HDR 
brachytherapy boost to residual vaginal disease and a left inguinal node prior to brachyablation of the right sidewall im-
plant. 
3 82F who presented with newly diagnosed T4N1M0 squamous cell carcinoma of the vagina with a left pelvic node measur-
ing 1.5 cm. She underwent EBRT to the pelvis alone, followed by an interstitial HDR boost to the vagina concurrent with 
brachyablation to the left pelvic node. 
4 60F who presented with recurrent endometrial adenocarcinoma, manifesting as an unresectable 5.1 × 4.4 cm left pelvic 
sidewall mass. She had originally presented with FIGO Stage II grade 1 disease, and was treated with surgical resection 
followed by adjuvant chemotherapy and whole pelvis EBRT with a vaginal cuff brachytherapy boost. She developed left 
pelvic lymphadenopathy two years later, which ultimately became refractory to systemic therapy after an initial period of 
response. She underwent brachyablation of the pelvic sidewall lesion nearly 61 months after her prior EBRT because of 
local progression, she underwent a second brachyablation procedure 2.93 months later. 
5 66M who presented with recurrent rectal adenocarcinoma, manifesting as an unresectable 2.4 × 3.3 cm lesion within the 
rectal lumen of his Hartmann pouch with partial involvement of the sphincter. He initially presented with T3N0M1 rectal 
adenocarcinoma (with two liver metastases), for which he underwent preoperative chemoradiotherapy followed by simul-
taneous wedge resection and abdominoperineal resection, and six cycles of adjuvant chemotherapy. Seventeen months 
later, he developed the local recurrence in question. He received brachyablation 22.9 months after the prior EBRT. 
6 17M who presented with an unresected 10.5 cm synovial sarcoma of the left medial plantar surface of the foot. He had 
initially presented several months prior with pulmonary metastases; he underwent six cycles of ifosfamide/doxorubicin 
chemotherapy with good response of his pulmonary lesions but not of the primary. He and his family refused surgery, and 
he was treated with EBRT followed by a brachyablation boost.
7 24M who presented with locally recurrent Ewing’s sarcoma of the right proximal tibia. He initially presented eight years 
earlier, and refused surgery, opting for definitive radiotherapy sandwiched between multiple cycles of chemotherapy. He 
had first developed a local recurrence four years earlier and again refused surgery. He tried chemotherapy but developed 
pulmonary metastases and eventually underwent a palliative debulking procedure of the recurrent primary three years 
before presentation for brachyablation. Despite further chemotherapy, he continued to have progressive pulmonary dis-
ease and within 22 months, he had a local recurrence measuring 2.5 cm. He again refused surgery and brachyablation was 
performed, roughly 82.7 months after his initial course of radiation for his gross disease.
8 27F who presented with a 6.1 cm, unresectable ectopic renal clear cell carcinoma involving the head of the pancreas and 
distal duodenum. She received brachyablation prior to EBRT.
9 58F who presented with an 8 cm paraaortic recurrence of endometrial adenocarcinoma. She underwent surgical resection 
and vaginal cuff brachytherapy for FIGO stage IA grade 1 endometrial adenocarcinoma five years prior to consideration 
of brachyablation. Four years after the vaginal cuff brachytherapy, she developed a paraaortic recurrence. She underwent 
systemic treatment; though this initially stabilized the lesion, it began to progress, growing to 8 cm. She received chemo-
radiation, followed by brachyablation.
10 61M who presented with a 10.5 cm para-aortic/aortocaval metastatic pheochromocytoma lesion. He had been diagnosed 
with metastatic disease at initial presentation over 20 years prior and had undergone multiple radionuclide treatments. 
Upon first appearance of this lesion, he underwent several systemic therapies and multiple cryoablation treatments. Since 
these failed, he ultimately presented for brachyablation. He only tolerated one fraction due to anxiety.
11 80F who presented with a 5.2 × 4.9 cm aortocaval lesion secondary to recurrent uterine carcinosarcoma. She initially pre-
sented with FIGO stage II disease, for which she underwent surgical resection followed by one cycle of adjuvant chemo-
therapy, discontinued due to adverse effects. The recurrence developed shortly thereafter and she underwent EBRT alone, 
followed by brachyablation.
12 53F who presented with a 1.5 cm metastatic lesion in the right lobe of the liver, secondary to clear cell/endometrioid ovarian 
cancer. Her original disease had been treated with surgical resection and adjuvant chemotherapy eight years prior. She 
developed intra-abdominal metastases within one year of completing adjuvant chemotherapy, and had since undergone 
multiple cycles of chemotherapy and ablative procedures for a total of four intra-abdominal recurrences. She presented for 
brachyablation with the aforementioned hepatic lesion as well as synchronous para-aortic lymphadenopathy once these 
lesions were determined to be refractory to chemotherapy. She underwent EBRT to the para-aortic region, followed by 
brachyablation to the right hepatic lobe lesion. 
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Patient Clinical summary
13 87F who presented with a 5.5 cm right flank mass secondary to metastatic clear cell renal carcinoma, She was initially 
treated with a right nephrectomy nearly a decade earlier; At the time of recurrence, she was considered to not be a surgical 
candidate and thus presented for brachyablation. 
14 62F who presented with a 2.8 cm left peri-renal lesion secondary to metastatic small bowel leiomyosarcoma. She pre-
sented with metastatic disease six months earlier and had completed chemotherapy one month prior to consideration of 
brachyablation. The peri-renal lesion in question showed no response to chemotherapy, though her other intra-abdominal 
lesions had responded. 
15 66F who presented with a 2.9 cm para-aortic nodal recurrence from endometrial papillary serous carcinoma. She had 
initially presented with FIGO stage IIIB disease, which was treated with neoadjuvant chemoradiation, followed by surgical 
resection, a vaginal brachytherapy boost, and adjuvant chemotherapy. She developed a left paraspinous recurrence 21 
months later and was treated with palliative radiotherapy followed by chemotherapy. Upon completing, she developed 
ureteral stenosis secondary to the aforementioned para-aortic node. She underwent brachyablation 7.7 months after 
completing her second course of radiotherapy. 
16 20M who presented with an 11.7 cm unresectable recurrent desmoid tumor. The patient initially presented 10 years earlier, 
shortly after diagnosis of Gardner’s syndrome. He was originally treated with surgical resection but ultimately had several 
local recurrences necessitating local ablative techniques and multiple chemotherapy trials. Two years prior to presentation for 
brachyablation, he experienced a recurrence that included the base of the small bowel mesentery and was thus unresectable; 
this lesion progressed on more aggressive systemic therapy, and he therefore underwent EBRT prior to a brachyablation boost. 
17   77M who presented with an unresectable 3.4 cm nodal recurrence of head and neck squamous cell carcinoma, abutting 
the left internal carotid artery and with left sternocleidomastoid and paraspinous muscle involvement. He had presented 
ten months earlier with a poorly differentiated SCC of unknown primary origin involving a level II neck node. He underwent 
definitive chemoradiation and initially had a good response but by eight months was found to have the aforementioned 
recurrence. He underwent brachyablation 10.1 months after his initial course of chemoradiation. Due to local progression, 
he underwent a second brachyablation 4.23 months later. 
18 76M with an unresectable 6.2 cm right supraclavicular mass secondary to a right upper chest melanoma. He initially pre-
sented with T1aN0 disease, which was treated with WLE alone 14 years prior to the recurrence in question. He eventually 
underwent axillary lymph node dissection, showing N3 disease; however, he refused adjuvant therapy of any kind. He was 
treated with EBRT followed by brachyablation. 
Table 3. Cont.
Fig. 1. Paired clinical photographs and image-guided high-dose-rate (IG-HDR) plans for five patients whose specific vignettes 
are found in the Supplementary Information section. (A) Patient 1, (B) patient 10, (C) top row, patient 6, bottom row, patient 7,  
(D) patient 19. The target volume is shown in red. The color code for the isodose colorwash is as follows: magenta, 200%; orange, 
150%; yellow, 110%; dark blue, 100%; green, 90%, light blue, 85%
A
C
B
D
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(55.6%), compared with one of nine patients (11.1%) 
treated with combination EBRT. Finally, four out of seven 
patients with prior EBRT had local failures (57.1%), com-
pared with two out of eleven patients without prior EBRT 
(18.1%). Adjuvant chemotherapy did not appear to influ-
ence local control with local failures in one of six patients 
who did not receive adjuvant chemotherapy (16.7%) and 
five of 12 patients who did receive (41.7%).
Among patients who had LC, eight had stable disease 
and four had partial responses. Three of the patients who 
had local failures appear to have had “marginal misses”, 
wherein disease progressed towards the edge of the 100% 
isodose line (an example is shown in Figure 3). Times to 
local failure were 1.03 and 2.87 months, respectively; two 
of these patients had repeat IG-HDR. One patient had 
a local failure (third recurrence overall) in 2.57 months 
and was treated with systemic therapy; she remains alive. 
The second had a local failure (third recurrence overall) in 
8.37 months and passed away 2.47 months later.
Organ-at-risk dosimetry and toxicity
Organ-at-risk dosimetric parameters are shown in Ta-
ble 5. Acute toxicities were minimal with five instances 
of grade 1 skin toxicity, three instances of grade 1 nau-
sea, four instances of grade 1 diarrhea, four instances of 
grade 1 fatigue, and two instances of grade 1 pain. One 
patient had grade 2 diarrhea, another had grade 2 uri-
nary frequency, one had grade 2 fatigue, and three had 
grade 2 pain. Another patient endorsed grade 2 anxiety 
after his first fraction, secondary to catheter placement. 
He discontinued treatment before his second and final 
fraction could be delivered. Otherwise, all patients who 
needed an overnight stay in the hospital tolerated having 
the brachytherapy catheters left in place overnight. No 
acute grade 3 or higher toxicities were seen.
With regards to chronic toxicity, one patient devel-
oped pelvic-cutaneous and vesico-perineal fistulas. Before 
IG-HDR was performed, the patient had prior chemora-
diation and an abdominoperineal resection procedure, fol-
lowed by adjuvant chemotherapy; at the time of IG-HDR, 
he had a bulky, painful local recurrence (Figure 4A). Sub-
sequent to IG-HDR, he had a significant clinical response, 
with improvement in pain and significant reduction in tu-
mor burden (Figure 4B). Unfortunately, he subsequently 
developed a bulky, painful local recurrence after his initial 
response, and it was at this point that the fistulization man-
ifested (Figure 4C). The patient also began to receive beva-
cizumab infusions as a component of systemic therapy one 
month after IG-HDR, which may have also contributed 
to his fistula formation [34]. Another patient developed 
chronic grade 1 lower extremity weakness as well as bone 
necrosis. She had a history of EBRT to the pelvis and due 
to progressive disease after IG-HDR, she underwent a sec-
ond course 2.93 months later. Both patients had bulky local 
recurrences that likely contributed to these sequelae.
Discussion
Despite significant technological improvements in 
both interventional radiology and radiation oncology, 
achieving LC remains challenging in certain scenarios, 
whether due to lesion size, proximity to critical struc-
tures, prior treatments, or a combination of the above. 
Table 4. Target coverage
Target parameter Mean Range
Planning target volume (ml)
Pelvis (n = 5) 144.2 1.9-496
Extremity (n = 2) 56.5 14-99
Abdomen/Retroperitoneum (n = 9) 91.3 15-223
Head/Neck (n = 2) 46.1 42.9-48
V100% (% of target volume receiving 
prescription dose)
88.7 69.6-100
V150% (% of target volume receiving 
150% of prescription dose)
52.9 29.7-90
D90% (% of prescription dose covering 
90% of target volume)
100.6 74.5-148
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Fig. 2. Kaplan-Meier curves for local control and overall survival. The numbers at risk are shown at the bottom of the plot
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While essential in the upfront treatment of localized dis-
ease, achieving LC is also important in the recurrent and/
or metastatic settings for symptomatic improvement and, 
in the setting of oligometastatic disease, improved out-
comes. Our data suggest that IG-HDR offers a nearly 60% 
chance of LC at one year in a heavily pre-treated popu-
lation for whom neither a purely interventional radiolo-
gy-based approach nor an EBRT approach were felt to be 
optimal. Of the eighteen patients treated, only two were 
treated for a localized primary, while the rest had recur-
rent lesions and/or systemic disease. Seven had prior 
EBRT and eight received EBRT in combination with IG-
HDR. Acute toxicities were mild with no grade ≥ 3 tox-
icities noted, though one patient discontinued treatment 
halfway through due to anxiety. Two patients had grade 
3 chronic toxicities; IG-HDR likely contributed but both 
patients also had bulky local recurrences contributing to 
their symptoms, and both had prior EBRT.
Several reports of outcomes following IG-HDR have 
been reported, primarily with regards to treating hepatic 
lesions [10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20], recurrent 
anorectal cancer [21, 22, 23, 24], lung lesions [25], and 
head/neck cancer [26, 27, 28, 29]. Series including more 
heterogeneous populations are limited. Bretschneider 
et al. recently reported the outcomes of 14 patients who 
received IG-HDR for metastatic melanoma lesions lo-
cated in the liver, lung, adrenals, lymph nodes, and kid-
neys [30]. The median lesion size was 1.5 cm, with a me-
dian dose of 19.9 Gy (EQD2 of 45.9 Gy). They reported 
Fig. 3. The image-guided high-dose-rate (IG-HDR) plan 
for patient 4 (shown on the left) is compared to a two-
month follow-up scan on the right, demonstrating growth 
of a lesion on the lateral surface of the ischium and erod-
ing through the bone into the pelvic sidewall. At the time 
of presentation for IG-HDR, disease was only visible 
medial to the ischium, and hence the bone itself was not 
targeted. The color code for the isodose colorwash is as 
follows: magenta, 200%; orange, 150%; yellow, 110%; dark 
blue, 100%; green, 90%, light blue, 85%
Table 5. Organ-at-risk dosimetric parameters from 
image-guided high-dose-rate brachytherapy (IG-HDR) 
plan
Organ-at-risk Dosimetric parameter (Gy)
D0.1cc
* D1cc D2cc
Pelvis (n = 5)
Small bowel 4.66 3.79 3.46
Sigmoid 0.355 0.255 0.215
Rectum 1.64 1.34 1.20
Bladder 3.02 2.72 2.49
Urethra 3.02 2.46 1.68
Extremity (n = 2)
Skin 2.63 2.28 2.18
Bone 5.73 4.72 4.14
Abdomen/Retroperitoneum (n = 9)
Small bowel 5.97 4.99 4.60
Ipsilateral kidney 5.43 4.53 4.11
Liver 2.11 1.72 1.56
Spinal cord 3.86 3.33 3.08
Head and neck (n = 2)
Skin 5.035 4.27 3.835
Mandible 1.65 1.32 1.21
Spinal cord 3.14 1.96 1.55
*Dx cc – maximum dose in Gy to “x” cc of the structure in question (where x = 0.1, 
1, or 2 cc)
Fig. 4. The clinical course for patient 1 is shown pictorially. On the left is the gross disease present at the time of IG-HDR treat-
ment. Tumor burden 4.5 months after treatment is shown in the middle. Unfortunately, the patient had subsequent progres-
sion, resulting in bulky local recurrence, shown on the right at one year following IG-HDR
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a median LC rate of 90% at five months. Image-guided 
interstitial high dose rate was well-tolerated, with two 
patients developing small pneumothoraces and one 
patient developing cholangitis. In general, the average 
diameter of the lesions treated in our cohort was larger 
at 5.8 cm (corresponding to an average planning target 
volume of 93.8 ml), and the average EQD2 for lesions 
treated with IG-HDR monotherapy was 36 Gy. Despite 
these differences, our LC rate of 79% at five months is 
consistent with the results reported by Bretschneider 
et al. The generally large lesion size and high-risk compo-
sition of our cohort could also explain why our one-year 
LC rate of 59% is slightly lower than the reported results 
from the other aforementioned IG-HDR series. Our low 
toxicity rates, on the other hand, are comparable.
Despite its effectiveness and tolerability in a wide 
variety of anatomic locations, the optimal indication for 
IG-HDR remains unclear. Both EBRT and intervention-
al radiology-ablation techniques have been well-studied 
and afford excellent probabilities of obtaining LC. How-
ever, many of the lesions in our series were either close to 
major vessels, close to other critical structures, and/or had 
a large diameter – all issues that can limit the appropriate-
ness of either EBRT or interventional radiology-ablation 
techniques [3, 4, 5, 6, 7, 8]. In a recent dosimetric study 
comparing stereotactic body radiation therapy (SBRT) 
and IG-HDR plans for liver lesions, investigators found 
that IG-HDR could provide intra-tumoral dose escalation 
and decreased low dose spill to surrounding tissues [35]. 
On the other hand, for small lesions, SBRT may be pre-
ferred. For example, Rwigema et al. reported a one-year 
LC rate of 100% following the use of SBRT for 44 unresect-
able nodal and soft-tissue oligometatases [36]. The medi-
an gross tumor volume was 18.7 ml, considerably smaller 
than that in our study. Thus, IG-HDR may be most ideal 
in situations where other means of obtaining LC are rela-
tively or absolutely contraindicated, as in the case of large 
lesion and/or lesions in close proximity to critical OARs.
Because of the small sample size, we did not attempt 
any statistical test to compare LC probabilities on the ba-
sis of anatomic site, EQD2, or combination with EBRT vs. 
IG-HDR alone. It is probable that the relatively improved 
LC with combination EBRT relates to the fact that most 
patients treated with IG-HDR alone had relative contra-
indications to combination EBRT. Further study will be 
needed to determine the adequate dose and fractionation 
for IG-HDR cases.
There are several limitations to this work. First, the 
treated population is heterogeneous, rendering it difficult 
to make firm conclusions about the efficacy of IG-HDR. 
The primary goal of this work was to determine the ef-
ficacy and safety of escalated doses of radiation in chal-
lenging treatment situations. Second, the employed defi-
nition of LC was based upon RECIST classification of 
treated lesions. Several patients had significant burden 
of disease and IG-HDR was performed with a goal of 
symptomatic relief. While at least one follow-up imaging 
study was required for inclusion in this report, several 
patients did not obtain further imaging, nor did we feel 
it was appropriate to request them to do so solely for this 
study. Thus, it is possible that some patients had LC for 
a longer interval than was reported here. Conversely, it 
is possible that post-treatment hyperemia could have ob-
scured the clear identification of a local failure; however, 
all images were reviewed by radiologists trained in uti-
lizing the RECIST criteria. Additionally, our data appear 
to show a strong dose-response relationship with higher 
EQD2 values associated with improved LC. As a result, 
one might argue that the patients who experienced poor 
LC in our study were underdosed. This may indeed be 
the case; as no clear OAR constraints and IG-HDR dosing 
guidelines were available for the relevant target locations 
at the time these patients were treated, doses were often 
chosen conservatively. Finally, the intention of IG-HDR 
as described herein is not to supplant other, more com-
monly used, and widely accessible ablative techniques 
but rather to provide an option in cases, for which those 
techniques may not be optimal.
Conclusions
In conclusion, IG-HDR appears to be an effective and 
safe joint interventional radiology/radiation oncology 
technique for achieving LC in patients with complex tu-
mor masses, for which other ablative techniques are rel-
atively contraindicated. Likely candidate lesions will be 
those that are large and/or in close proximity to critical 
structures or vessels.
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